Bioresponsive Chimaeric Polymersomes Mediate Sustained and Liver-Specific Transfection .

The silencing of disease-causing genes with small interfering RNA () offers a particularly effective therapeutic strategy for different disorders; however, its clinical efficacy relies on the development of nontoxic and tissue-specific delivery vehicles. Herein, we report that bioresponsive chimaeric polymersomes (BCP) with short poly(ethylenimine) as inner shell mediate highly efficacious, sustained, and liver-specific transfection . BCP exhibited remarkable encapsulation efficiencies of (95-100%) at feeding contents of 15-25 wt %, to afford stable, small-sized (55-64 nm), and neutral-charged BCP-. -Loaded BCP (BCP-) outperformed lipofectamine counterparts and silenced 93% of mRNA in HepG2 cells at 50 nM without inducing cytotoxicity. Intriguingly, the studies using wild-type C57BL/6 mice revealed that BCP- preferentially accumulated in the liver, and a single dose of 4.5 mg/kg achieved over 90% downregulation of mRNA for at least 10 days. The systemic administration of BCP- at 4.5 mg/kg every 2 weeks or 1.5 mg/kg weekly in diet-induced obese mice could also achieve up to 80% silencing of mRNA. The liver specificity and silencing efficacy of BCP- could further be improved by decorating it with the trivalent -acetylgalactosamine (TriGalNAc) ligand. These bioresponsive and liver-specific chimaeric polymersomes provide an enabling technology for therapy of various liver-related diseases.